TY - JOUR
T1 - Instrument selection using the OMERACT filter 2.1
T2 - The OMERACT methodology
AU - Beaton, Dorcas E.
AU - Maxwell, Lara J.
AU - Shea, Beverley J.
AU - Wells, George A.
AU - Boers, Maarten
AU - Grosskleg, Shawna
AU - Bingham, Clifton O.
AU - Conaghan, Philip G.
AU - D’Agostino, Maria Antonietta
AU - De Wit, Maarten P.
AU - Gossec, Laure
AU - March, Lyn M.
AU - Simon, Lee S.
AU - Singh, Jasvinder A.
AU - Strand, Vibeke
AU - Tugwell, Peter
N1 - Funding Information:
From the Institute for Work & Health and Institute for Health Policy Management and Evaluation, University of Toronto, Toronto; Clinical Epidemiology Program, and Centre for Practice-Changing Research, Ottawa Hospital Research Institute; Cardiovascular Research Methods Centre, University of Ottawa Heart Institute; Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ontario, Canada; Department of Epidemiology and Biostatistics, and Department of Medical Humanities, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands; Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland; Medicine Service, VA Medical Center; Department of Medicine, School of Medicine, University of Alabama; Division of Epidemiology, School of Public Health, University of Alabama, Birmingham, Alabama; SDG LLC, Cambridge, Massachusetts, USA; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; UK National Institute for Health Research (NIHR) Leeds Biomedical Research Centre, Leeds, UK; Hôpital Ambroise Paré, Rheumatology Department, Boulogne-Billancourt; INSERM U1173, Laboratoire d’Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University, Saint-Quentin en Yvelines; Sorbonne Université; Pitié Salpêtrière hospital, AP-HP, Rheumatology Department, Paris, France; Sydney Medical School, Institute of Bone and Joint Research and Department of Rheumatology, Royal North Shore Hospital, St. Leonards, Australia. PGC is funded in part by the NIHR Leeds Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the UK National Health Service, the NIHR, or the Department of Health. JAS is supported by the resources and the use of facilities at the VA Medical Center at Birmingham, Alabama. LMM is a Principal Investigator on the Australian Rheumatology Association Database, which has received arms-length funding from AbbVie Australia, Pfizer Australia, Janssen Australia, and Eli Lilly Australia. OMERACT is a registered nonprofit independent medical research organization whose goal is to improve and advance the health outcomes for patients with musculoskeletal conditions. OMERACT receives unrestricted educational grants from the American College of Rheumatology, the European League of Rheumatology, and several pharmaceutical companies. The grants are used to support fellows, international patient groups, and a major international biennial conference that results in many peer-reviewed publications. The views expressed in this article are those of the authors and do not necessarily reflect the position of the US Department of Veterans Affairs or the US government.
Publisher Copyright:
. The Journal of Rheumatology Copyright © 2019. All rights reserved.
PY - 2019/8/1
Y1 - 2019/8/1
N2 - Objective. Outcome Measures in Rheumatology (OMERACT) Filter 2.1 revised the process used for core outcome measurement set selection to add rigor and transparency in decision making. This paper describes OMERACT’s methodology for instrument selection. Methods. We presented instrument selection processes, tools, and reporting templates at OMERACT 2018, introducing the concept of “3 pillars, 4 questions, 7 measurement properties, 1 answer.” Truth, discrimination, and feasibility are the 3 original OMERACT pillars. Based on these, we developed 4 signaling questions. We introduced the Summary of Measurement Properties table that summarizes the 7 measurement properties: truth (domain match, construct validity), discrimination [test-retest reliability, longitudinal construct validity (responsiveness), clinical trial discrimination, thresholds of meaning], and feasibility. These properties address a set of standards which, when met, answer the one question: Is there enough evidence to support the use of this instrument in clinical research of the benefits and harms of treatments in the population and study setting described? The OMERACT Filter 2.1 was piloted on 2 instruments by the Psoriatic Arthritis Working Group. Results. The methodology was reviewed in a full plenary session and facilitated breakout groups. Tools to facilitate retention of the process (i.e., “The OMERACT Way”) were provided. The 2 instruments were presented, and the recommendation of the working group was endorsed in the first OMERACT Filter 2.1 Instrument Selection votes. Conclusion. Instrument selection using OMERACT Filter 2.1 is feasible and is now being implemented.
AB - Objective. Outcome Measures in Rheumatology (OMERACT) Filter 2.1 revised the process used for core outcome measurement set selection to add rigor and transparency in decision making. This paper describes OMERACT’s methodology for instrument selection. Methods. We presented instrument selection processes, tools, and reporting templates at OMERACT 2018, introducing the concept of “3 pillars, 4 questions, 7 measurement properties, 1 answer.” Truth, discrimination, and feasibility are the 3 original OMERACT pillars. Based on these, we developed 4 signaling questions. We introduced the Summary of Measurement Properties table that summarizes the 7 measurement properties: truth (domain match, construct validity), discrimination [test-retest reliability, longitudinal construct validity (responsiveness), clinical trial discrimination, thresholds of meaning], and feasibility. These properties address a set of standards which, when met, answer the one question: Is there enough evidence to support the use of this instrument in clinical research of the benefits and harms of treatments in the population and study setting described? The OMERACT Filter 2.1 was piloted on 2 instruments by the Psoriatic Arthritis Working Group. Results. The methodology was reviewed in a full plenary session and facilitated breakout groups. Tools to facilitate retention of the process (i.e., “The OMERACT Way”) were provided. The 2 instruments were presented, and the recommendation of the working group was endorsed in the first OMERACT Filter 2.1 Instrument Selection votes. Conclusion. Instrument selection using OMERACT Filter 2.1 is feasible and is now being implemented.
KW - Health status indicator
KW - OMERACT
KW - Outcome assessment
KW - Outcome measures
KW - Reliability
KW - Reproducibility of results
KW - Validity
UR - http://www.scopus.com/inward/record.url?scp=85070237424&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070237424&partnerID=8YFLogxK
U2 - 10.3899/jrheum.181218
DO - 10.3899/jrheum.181218
M3 - Article
C2 - 30709952
AN - SCOPUS:85070237424
SN - 0315-162X
VL - 46
SP - 1028
EP - 1035
JO - Journal of Rheumatology
JF - Journal of Rheumatology
IS - 8
ER -